Using tranexamic acid to reduce bleeding during facelift surgery
Topical and Local TXA in Facelifts - A Randomized Controlled Double Blinded Study
This study tests if using tranexamic acid can help reduce bleeding during facelift surgery compared to a saline solution.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Minnesota Academic / other |
| Locations | 1 site (Minneapolis, Minnesota) |
| Trial ID | NCT06345833 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of tranexamic acid (TXA) in preventing excessive bleeding during facelift surgeries. Participants will receive TXA applied to one side of the face while the other side will receive a saline solution for comparison. The study will evaluate different concentrations and methods of TXA application, including a combination with local anesthetics. The goal is to determine if TXA can significantly reduce hemorrhage during these procedures.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who are scheduled for facelift surgery and deemed fit by their surgeon.
Not a fit: Patients under 18, those with a history of adverse reactions to tranexamic acid, or non-English speakers may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to safer facelift surgeries with reduced bleeding and improved recovery for patients.
How similar studies have performed: Previous studies have shown that TXA can effectively reduce bleeding in various surgical settings, suggesting potential success for this novel application in facelift surgery.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Eligible participants will consist of all regular clinic patients who elect and are deemed fit by the surgeon to undergo facelift surgery, including patients undergoing ancillary procedures * age 18 and older * English speaking. Exclusion Criteria: * younger than 18 * previously had an adverse reaction to tranexamic acid * non-English speaking * patients who elect not to participate or withdraw from the study.
Where this trial is running
Minneapolis, Minnesota
- University of Minnesota — Minneapolis, Minnesota, United States (Recruiting)
Study contacts
- Principal investigator: Jenna Van Beck, MD — University of Minnesota
- Study coordinator: Jenna Van Beck, MD
- Phone: (612) 626-5900
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.